Clevudine: Preliminary Phase III data

In the open-label, Korean Phase III trial (study 303) in 55 treatment-naïve patients, at week 48, 68% of hepatitis B antigen (HBeAg)-positive patients and 100% of HbeAg-negative patients were PCR nega...